Astria Therapeutics Inc.
- Address
- 22 Boston Wharf Road, Floor 10
Sponsor Overview
Specializations
Hereditary Angioedema
Astria Therapeutics Inc. focuses its clinical research on hereditary angioedema, with studies spanning both Type 1 and Type 2 HAE. The programme centers on preventing attacks and evaluating treatment options for people living with this rare disease.
- Attack prevention in hereditary angioedema
- Type 1 and Type 2 HAE
- Adult and adolescent populations
The sponsor’s current trial portfolio includes multiple active studies across several countries, with research sites supporting the clinical evaluation of HAE in both long-term and preventive care settings.
Long-term Safety and Tolerability
One major area of interest is the long-term safety and tolerability of investigational therapies for hereditary angioedema. These studies examine sustained treatment use in adults and adolescents, with attention to ongoing treatment exposure over time.
- Long-term treatment safety
- Tolerability in repeated use
- Chronic management of HAE
This focus reflects a therapeutic emphasis on maintaining control of angioedema attacks while monitoring how therapies are received in routine preventive use.
Preventive Therapy Development
The sponsor is actively involved in research on preventive treatment for hereditary angioedema, including evaluation of therapies intended to reduce the frequency of attacks. This includes studies in adults as well as adolescents with HAE.
- Prophylaxis for HAE attacks
- Adult preventive treatment
- Adolescent treatment evaluation
These trials support the development of subcutaneous treatment approaches for people needing ongoing protection from recurrent hereditary angioedema episodes.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants with Hereditary Angioedema (The ALPHA-STAR Trial) |  Bulgaria Czechia Germany Poland | Not Recruiting |
| A Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema |  Austria Bulgaria Czechia France Germany Hungary Italy Poland Portugal Spain The Netherlands | Recruiting |
| Efficacy and Safety Evaluation of Navenibart in Hereditary Angioedema: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial | Austria Bulgaria Czechia France Germany Hungary Italy Poland Portugal Spain The Netherlands | Not Recruiting |
| Evaluation of Long-Term Safety and Efficacy of STAR-0215 in Adult Patients with Type 1 or Type 2 Hereditary Angioedema | Bulgaria Czechia Germany Poland | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 34 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities4 trials165 other sponsors
Partnered Research Centres
34 centres- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Via Giovanni Battista Grassi 74, 20157 Milan
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Largo Filippo Turati 62, 10128 Turin
- Address
- Strada Statale 554 N. 1, 09042 Monserrato
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Astria Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.